Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2302 - Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French Group of Endocrine Tumors (GTE)

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Kathleen Dekeister Geoffroy

Citation

Annals of Oncology (2019) 30 (suppl_5): v194-v197. 10.1093/annonc/mdz245

Authors

K. Dekeister Geoffroy1, L. Francois2, T. Walter1, O. Hentic Dhome3, A. Cachier4, G. Cadiot5, P. Nazeyrollas6, P. Afchain7, S. Ederhy8, C. Lepage9, J. Eicher10, R. Coriat11, L. Cabanes12, E. Baudin13, S. Dominguez14, F. Delelis15, J. Forestier16, C. Lombard Bohas16

Author affiliations

  • 1 Oncology, Pavillon E, UJOMM, Hôpital Edouard Herriot, 69003 - Lyon/FR
  • 2 Cardiology, Hôpital Louis Pradel / Groupement Hospitalier Est Cardiologie E, 69500 - Bron/FR
  • 3 Gastroenterology, Beaujon Hospital APHP, 92110 - Clichy/FR
  • 4 Cardiology, Beaujon Hospital APHP, 92110 - Clichy/FR
  • 5 Gastroenterology, CHU de Reims - Hôpital Robert Debré, 51092 - Reims/FR
  • 6 Cardiology, CHU de Reims - Hôpital Robert Debré, 51092 - Reims/FR
  • 7 Medical Oncology, Hôpitaux Universitaires Est Parisien, Hôpital Saint Antoine, 75 571 - Paris/FR
  • 8 Cardiology, Hôpitaux Universitaires Est Parisien, Hôpital Saint Antoine, 75 571 - Paris/FR
  • 9 Hepato Gastroenterology And Digestive Oncology, CHU Dijon, 21079 - Dijon/FR
  • 10 Cardiology, CHU Dijon, 21079 - Dijon/FR
  • 11 Gastroenterology, Hôpital Cochin, 75014 - Paris/FR
  • 12 Cardiology, Hôpital Cochin, 75014 - Paris/FR
  • 13 Nuclear Medicine And Endocrine Oncology, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 14 Oncohematology, Hôpital St Vincent de Paul, 59000 - Lille/FR
  • 15 Cardiology, Hospital Saint Philibert GCS-GHICL, 59462 - Lomme/FR
  • 16 Oncology, Hopital Edouard Herriot Pav. E bis, 69437 - Lyon/FR
More

Resources

Abstract 2302

Background

Neuroendocrine tumors (NET) represent a heterogeneous group of rare tumors, some of them secreting serotonin resulting in the carcinoid syndrome (CS). CHD is an integral part of this syndrome but remains poorly understood. The GTE is conducting a national survey of patients at risk for CHD aiming at evaluating the occurrence & progression rates of CHD, the frequency & results of cardiac surgery, and patient outcomes as well as the role of clinical characteristics and biomarkers as predictive markers; 600 patients are expected over a 5-year period with a 10-year follow-up. We herein present the study status at one year.

Methods

Patients with a metastatic ileum or bronchial NET, or any NET with a CS or 5HIAA levels greater than at least twice the upper normal range, seen by a NET specialist and a referee cardiologist are eligible. Clinical, pathological, biological parameters and previous treatments are collected. A transthoracic echocardiography is realised at inclusion and at least every year.

Results

From March 2018 to March 2019, 167 patients from 8 centers were included. Median [range] time from NET diagnosis to study inclusion was 56 months [0-501]. Median age was 66 years [34-86] with a male preponderance (53%); 85% had ileum NETs, 8% lung NETs, and 7% other NETs with CS or elevated 5HIAA; 100% had metastatic disease. Most of them have been pretreated: somatostatin analogs 96%, surgery of primary tumor 81% or metastasis 34%, liver embolization 24%, peptide receptor radionuclide therapy 19%, chemotherapy 16%, targeted therapy 12%, radiofrequency ablation 6%, interferon 2%. At inclusion, 81 patients (49%) had a CS, 67% with flushing, 68% with diarrhea. CHD was documented in 22 (13%) patients, all of them had tricuspid disease and simultaneous pulmonary, mitral and/or aortic disease for respectively 13, 3 and 1 of them; 14 patients with CHD had a CS. Seven patients underwent cardiac surgery for CHD.

Conclusions

The first large prospective multicentric study about CHD is ongoing. Preliminary results confirm the feasibility of the study with nearly 170 patients included in one year and 13% of CHD. The inclusion of new patients and 10-year follow-up will allow a better knowledge of the current incidence, progression and prognosis of CHD.

Clinical trial identification

NCT03498040.

Editorial acknowledgement

Legal entity responsible for the study

French Group of Endocrine Tumors (GTE).

Funding

IPSEN.

Disclosure

G. Cadiot: Advisory / Consultancy: Novartis; Advisory / Consultancy: Ipsen; Advisory / Consultancy: AAA; Advisory / Consultancy: Keocyt. P. Nazeyrollas: Honoraria (self), Honoraria (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Novartis; Honoraria (self), Non-remunerated activity/ies: MSD; Honoraria (institution): Sanofi; Honoraria (institution): novo-nordisk; Travel / Accommodation / Expenses, Non-remunerated activity/ies: actelion; Travel / Accommodation / Expenses, Non-remunerated activity/ies: Bayer; Non-remunerated activity/ies: Servier; Non-remunerated activity/ies: bms. P. Afchain: Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: Ipsen. F. Delelis: Honoraria (self): Novartis; Honoraria (self): boehringer. J. Forestier: Honoraria (self): Amgen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bayer; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Honoraria (self): Servier. C. Lombard Bohas: Advisory / Consultancy: Ipsen; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: AAA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings